Objective. Skin fibrosis is the predominant feature of SSc and arises from excessive extracellular matrix deposition. Glycosaminoglycans are macromolecules of the extracellular matrix, which facilitate Na + accumulation in the skin. We used 23 Na-MRI to quantify Na + in skin. We hypothesized that skin Na + might accumulate in SSc and might be a biomarker for skin fibrosis.
Introduction
Skin and organ fibrosis is a leading cause of morbidity and mortality in SSc [1] . Fibrotic tissue arises from the excessive accumulation of extracellular matrix (ECM) released by pathologically activated fibroblasts [2] . Although fibrosis has long been considered a unidirectional process, growing evidence suggests that the fibrotic tissue feeds back to maintain the aberrant activation of fibroblasts and to enhance ECM release further. GAGs are integral parts of the ECM and play a central role in inducing and maintaining the activated state of fibroblasts by direct interactions and/or modulation of cytokine signalling [3] . In SSc, fibroblasts release increased amounts of hyaluronan and other GAGs, which accumulate and may propel fibrosis [4, 5] . GAGs are negatively charged macromolecules, and their polyanionic character allows them to bind cations [6] . We demonstrated earlier that GAGs make the skin into a major Na + storage depot, which is actively regulated by immune cells [68] . To translate these findings clinically, we introduced and validated 23 
Methods
The study was approved by the local Ethics Committee of the University of Erlangen-Nü rnberg (no. 3948) and was conducted according to the principles of the Declaration of Helsinki. All study participants provided written informed consent. In this observational casecontrol study, we compared skin Na + intra-individually in SSc patients and with healthy control subjects. Besides, we prospectively followed-up on SSc disease activity within 1 year. We examined 12 consecutive patients with dcSSc, who regularly present to our outpatient university clinic, and 21 age-and sex-matched normal controls. Inclusion criteria were the diagnosis of SSc according to the new ACR/EULAR classification [12] and the affiliation to the diffuse cutaneous subset of the disease according to the 1988 criteria of LeRoy et al. [13] . Furthermore, solely patients with skin involvement of the forearm, according to clinical assessment by the modified Rodnan skin score (mRSS) at the time of 23 Na-MRI, were included. Patients with the diffuse cutaneous form of the disease were chosen for this pilot study, because we expected more severe fibrosis at the forearm, the primary site of measurement. Healthy control subjects presented without any history of chronic illness, normal laboratory findings and, except for two (one with hormonal replacement therapy and one with L-thyroxine substitution), did not take any regular medication (see Supplementary Table S1 for further details). The same experienced rheumatologist performed the mRSS on all patients on the day of the 23 Na-MRI measurements and at the follow-up 12 months later to determine skin involvement in SSc. To assess changes in skin fibrosis, the initial complete mRSS (from 17 sites) was subtracted from the follow-up mRSS after 12 months and correlated with skin Na + content from 23 Na-MRI analysis. The EULAR Scleroderma Trials and Research Disease Activity Score (EUSTAR DAS) was determined before 23 Na-MRI measurements according to the proposed assessment by Valentini et al. [14] . Blood samples were obtained and blood pressure was assessed prior to the MRI measurement. We introduced 23 Na-MRI to quantify tissue Na + in human skin and muscle [10] . In this study, we measured skin Na + content in the region of the left dorsal forearm (10 cm proximal of the wrist) and the left dorsal lower leg (at the largest circumference) with a 23 Na volume coil (Stark-Contrast, Erlangen, Germany) and a 3.0 T MRI scanner (Magnetom Verio; Siemens Healthcare, Erlangen, Germany). Fibrosis of the lower leg is more rarely observed in dcSSc patients and was therefore selected to serve as an intra-individual control. For analysis, the extremities were placed on a cylindrically shaped surface to avoid deviation in the Z-axis. The extent of the skin measurement sites in the XY-axis is indicated by arrows within the figures. According to the resolution specifications (see below), 30 mm of skin Na + was averaged in the Z-axis. We used a two-dimensional Fast Low-Angle Shot (FLASH) sequence (total acquisition time, TA = 13.7 min; echo time, TE = 2.07 ms; repetition time, TR = 100 ms; flip angle, FA = 90 ; 128 averages; resolution, 3 mm Â 3 mm Â 30 mm). Four tubes containing aqueous solutions with 40, 30, 20 and 10 mmol/l sodium chloride served as calibration standards by relating intensity to a concentration in a linear trend analysis. In parallel, we quantified tissue water content by 1 H-MRI, using a fat-saturated inversion recovery sequence with spin density contrast (inversion time, TI = 210 ms; TA = 6.29 min; TE = 12 ms; TR = 3 s; FA 1/ 2 = 90 /180 ; resolution, 1.5 mm Â 1.5 mm Â 5 mm). The 10 mmol/l sodium chloride tube served as a calibration standard for tissue water.
Data are expressed as the mean (S.D.). Data were analysed by Student's unpaired and paired t test and Pearson's correlation coefficient, using SPSS software (version 21.0). Values of P <0.05 were considered to indicate statistical significance.
Results
All SSc patients had fibrotic skin at the forearm (first site of 23 Na-MRI measurement), and 11 out of 12 showed no clinical skin involvement at the lower leg (second site of measurement). Control subjects had no skin disease. Patients and controls were matched for age and BMI and showed similar blood pressure. Characteristics of the study population are further detailed in Supplementary Table S1. We found significantly higher skin Na + at the fibrotic forearm of We next tested the hypothesis that unaffected skin of the lower leg showed normal Na + content in SSc patients.
We found that Na + content was higher in lesional skin of the forearm compared with the non-lesional skin of the same patients' lower limb [26.2 (4.8) vs 19.2 (3.4) mmol/l, P < 0.01; Fig. 1D and F) . Na + content in the non-fibrotic skin of SSc patients were not different from skin Na + content in our healthy control subjects [17.4 (3.0) vs 19.2 (3.4) mmol/l, P = 0.16; Fig. 1E ].
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The mRSS is the clinical standard method to assess skin fibrosis in SSc. The mRSS does not only assess skin thickening but, at least to some degree, also fibrotic skin tethering. Skin Na + content was poorly correlated with the local mRSS (at the site of measurement, 03, R 2 = 0.02) or the total mRSS (17 sites, 051, R 2 = 0.12). In contrast, however, we found a steep direct relationship between tissue Na + accumulation and the change of the total mRSS within 12 months (R 2 = 0.68; Fig. 2A) . Likewise, the EUSTAR DAS, developed to detect disease activity in clinical studies [14] , and skin Na + were directly correlated (R 2 = 0.48; Fig. 2B ).
Discussion
Using 23 Na-MRI, our study demonstrates increased Na + content in the involved skin of patients with SSc as well as a correlation between Na + content and progression of skin fibrosis. We previously introduced 23 Na-MRI as a non-invasive technique to quantify the Na + content of tissues. By using calibration standards, 23 Na-MRI can be easily standardized to produce very objective and reliable results. Importantly, 23 Na-MRI does not require gadolinium or other contrast dyes [911] , which are associated with the development of nephrogenic systemic fibrosis. Using 23 Na-MRI, we discovered earlier that hypertensive patients store larger amounts of Na + in tissues than normotensive healthy controls [9, 10] . In addition, 23 Na-MRI revealed that cutaneous infections can trigger local salt accumulation in humans. Local high-salt conditions in skin boost pro-inflammatory macrophage function, thereby helping to ward off infections [15] . Previously, we demonstrated that skin is the major Na + storage depot of the human body. Negatively charged hyaluronans and other GAGs serve as the binding sites for Na + in the skin. GAGs have been associated with important regulatory roles during physiological and pathological fibrogenesis. Although increased levels of these ECM molecules promote fibroblast activation and proliferation during early stages of wound healing [3] , a high and persistent expression in fibrotic diseases might have deleterious consequences, resulting in a vicious circle of persistent fibroblast activation and uncontrolled ECM deposition. Additionally, recent evidence indicates that a high Na + concentration itself promotes fibrosis in the skin via the epithelial Na + channel in keratinocytes [16] .
FIG. 1 23
Na-MRI detects increased Na + in fibrotic SSc skin and discriminates between affected and non-affected skin (AC) Skin Na + (A) and water content (B) of SSc patients (n = 12) and age-matched controls (n = 21) quantified by In line with these pathophysiological considerations, we observed in our study that skin Na + was increased in patients with active and progressive disease, who were characterized by an increasing mRSS. In contrast, low skin Na + amount was associated with a regression of skin fibrosis. Although additional studies are needed to investigate whether Na + itself is involved in the disease process or if it is a secondary phenomenon attributable to increased ECM levels, our data suggest that skin Na + might evolve as a sensitive biomarker for disease activity of SSc skin fibrosis. Outcome measures to assess skin fibrosis objectively are lacking in clinical practice. The semi-quantitative mRSS performs fairly well, with low intra-and interobserver variability when performed by experienced examiners. Nevertheless, even then standardization of the scoring is difficult [17, 18] . In our study, 23 Na-MRI reliably discriminated fibrotic from non-fibrotic and normal skin. Although the same experienced examiner assessed the mRSS in all patients at all visits, the correlation between lesional Na + accumulation and the local mRSS was poor. This finding may not be surprising, because the mRSS does not solely measure skin thickness but is also susceptible to skin tethering, even when done by experienced examiners. Furthermore, the local assessment of the mRSS is coarse, with only four grades to scale the extent of skin fibrosis. Importantly, studies with other imaging techniques, such as ultrasonography, had also produced poor correlations of skin thickness and the local mRSS, which supports our interpretation [19, 20] . We are aware of several shortcomings. First and foremost, as a result of the low incidence of SSc and our focus on the diffuse cutaneous subset, the patient cohort is small and does not reflect the complete spectrum of SSc skin disease. Future studies are needed to investigate Na + content in a larger number of patients, different ethnicities and varying disease subtypes. Second, follow-up measurements by 23 Na-MRI should explore whether Na + as a surrogate of skin fibrosis is sensitive to change and could therefore be used to assess the disease-modifying efficacy of novel therapies. In contrast to the mRSS and other imaging modalities, the 23 Na-MRI scans could be evaluated by central reference centres during clinical trials to ensure highly consistent readings. Finally, to gain a better understanding of the close correlation of skin Na + content with the change of the mRSS, molecular studies including skin biopsies are needed to strengthen our knowledge on the increased amount of Na + in the fibrotic tissue.
We present the first evidence that skin Na + homeostasis is altered in a human skin disease. Skin Na + amount assessed by non-invasive 23 Na-MRI may serve as indicator of active fibrotic disease. Future studies are necessary to validate and expand these findings.
Supplementary data
Supplementary data are available at Rheumatology Online.
